As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

To raise awareness of GBS and CIDP, GBS|CIDP Foundation International is kicking off the GBS: 110 Years, 110 Stories campaign, which will feature 110 stories, presented in short videos, from all ...

An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated peripheral nerve disorder that is challenging to diagnose, particularly in the absence of reliable biomarkers. The goals ...

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...

KING OF PRUSSIA, Pa., Dec. 9, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration ...

KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...